China Enters CAR-T Era with Fosun-Kite Yescarta Approval
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look…
Address: 4th Floor, 4/B, 233 Zhen Ning Lu
Rong Xuan Building
200050 – Shanghai / CHINA
Tel: +(86) 151 1797 6292
Web: http://www.acropolis-associates.com/
We assist multinational organizations, small and medium sized enterprises as well as smaller niche companies to attract, recruit and retain outstanding executives and senior managers through our specialist search techniques as well as through our strategic leadership consultancy services.At Acropolis-Associates, our outstanding staff is committed to provide its clients with executives, professionals and specialists whose skills will enhance and improve your business performance and profitability.Acropolis-Associates, professional recruitment consultancy, is committed to deliver the very best talent to its international clients. We operate from offices covering USA, France and China. Our talented professionals pursue the highest level of integrity and quality in providing a clear portfolio of services: executive search, recruitment, placement, and staff integrity.For more than 9 years, Acropolis-Associates has been devoted in delivering its services to organizations by strengthening management teams and their international staff.
» Executive Search
» Recruitment / Placement
» Corporate Fraud Alert (CFA)
» Building an Ethical Framework (BEF)
» Staff & Suppliers Integrity investigation (SSII)
» Education, Study abroad (China – USA / China – Europe)
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look…
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the latest round of price cuts for off-patent…
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its strategically important China business. van Acker takes the helm against…
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation with Sanofi China’s Irene Deng, looks at how Chinese pharmaceutical regulations have evolved and…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach…
In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem. …
The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.…
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player…
Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen…
The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai International Medical Center (SIMC) jointly established a Rehabilitation Medicine Center for stroke patients with the mission…
See our Cookie Privacy Policy Here
